Provided by Tiger Trade Technology Pte. Ltd.

ProShares Ultra Health Care

57.05
-0.1900-0.33%
Post-market: 57.050.00000.00%19:30 EDT
Volume:22.10K
Turnover:1.26M
Market Cap:92.42M
PE:- -
High:57.19
Open:57.03
Low:56.45
Close:57.24
52wk High:64.60
52wk Low:42.76
Shares:1.62M
Float Shares:1.62M
Volume Ratio:1.13
T/O Rate:1.36%
Dividend:0.63
Dividend Rate:1.11%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sanofi, Regeneron's Dupixent Successors Might Fall Short of Rivals

Dow Jones
·
Oct 02

Novartis Strikes up to $7.8 Billion mRNA Deal with China's Abogen

Reuters
·
Oct 02

Perrigo Co. PLC Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Oct 02

Merck & Co. Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

Simply Wall St.
·
Oct 02

US Stocks on the MOVE-Cardinal Health, nVent, Acuity

Reuters
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Merck's Tulisokibart Data From Hidradenitis Suppurativa Trial Looks Solid, UBS Securities Says

MT Newswires Live
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Health Insurers Fall After UnitedHealthcare, Aetna Announce 2027 Plan Designs

Reuters
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

AbbVie Says Phase 3 Trials Show Rinvoq Vitiligo Repigmentation Gains Extend to Week 76

Reuters
·
Oct 01

Abbvie - Phase 3 Studies Show Continued Repigmentation with Rinvoq Through Week 76

THOMSON REUTERS
·
Oct 01

Abbvie - Rinvoq Plus NB-Uvb Shows Higher Repigmentation than Rinvoq Alone

THOMSON REUTERS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

AbbVie to Host Third-Quarter 2026 Earnings Call Webcast

Reuters
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Oct 01